Cognetivity Neurosciences Stock Current Valuation

CGNSF Stock  USD 0  0  42.86%   
Valuation analysis of Cognetivity Neurosciences helps investors to measure Cognetivity Neurosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
0
Please note that Cognetivity Neurosciences' price fluctuation is out of control at this time. Calculation of the real value of Cognetivity Neurosciences is based on 3 months time horizon. Increasing Cognetivity Neurosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cognetivity pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Cognetivity Neurosciences. Since Cognetivity Neurosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cognetivity Pink Sheet. However, Cognetivity Neurosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.004 Real  0.00328 Hype  0.003462
The real value of Cognetivity Pink Sheet, also known as its intrinsic value, is the underlying worth of Cognetivity Neurosciences Company, which is reflected in its stock price. It is based on Cognetivity Neurosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cognetivity Neurosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
0
Real Value
38.73
Upside
Estimating the potential upside or downside of Cognetivity Neurosciences helps investors to forecast how Cognetivity pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cognetivity Neurosciences more accurately as focusing exclusively on Cognetivity Neurosciences' fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
0.00038.73
Details

Cognetivity Neurosciences Company Current Valuation Analysis

Cognetivity Neurosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Cognetivity Neurosciences Current Valuation

    
  15.68 M  
Most of Cognetivity Neurosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cognetivity Neurosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Cognetivity Neurosciences has a Current Valuation of 15.68 M. This is 99.89% lower than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The current valuation for all United States stocks is 99.91% higher than that of the company.

Cognetivity Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cognetivity Neurosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cognetivity Neurosciences could also be used in its relative valuation, which is a method of valuing Cognetivity Neurosciences by comparing valuation metrics of similar companies.
Cognetivity Neurosciences is currently under evaluation in current valuation category among its peers.

Cognetivity Fundamentals

About Cognetivity Neurosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cognetivity Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognetivity Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognetivity Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Cognetivity Pink Sheet

Cognetivity Neurosciences financial ratios help investors to determine whether Cognetivity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cognetivity with respect to the benefits of owning Cognetivity Neurosciences security.